Who We Are

Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life.  Our focus is on the treatment of medical conditions where there is significant unmet clinical need.

We are developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of inflammatory and immune, neurological, and cardiovascular disease. We have two ongoing clinical studies – a Phase 2 study in ulcerative colitis being conducted with Pfizer and a Phase 2 study in ischemic stroke – and overall five clinical stage programs in inflammatory bowel disease, stroke, graft-versus-host disease, acute myocardial infarction and solid organ transplant.

Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the United States and Europe to further develop its platform and products.

In The News RSSView All

"Regenerative medicine has the potential to transform healthcare, enabling us to effectively treat many areas of unmet medical need where current forms of medicine are largely ineffective. This will allow us to help many patients, as well as make healthcare more cost effective."

Dr. Gil Van Bokkelen
Chairman & CEO, Athersys, Inc.